Amgen rides Repatha renaissance as cardio wins keep cholesterol med's momentum rolling

As Amgen’s flagship PCSK9 cholesterol drug Repatha enjoys a bit of a renaissance on the back of impressive cardiovascular risk reduction data last year, the company is confident it can keep that mo | As Amgen’s flagship PCSK9 cholesterol drug Repatha enjoys a bit of a renaissance on the back of impressive cardiovascular risk reduction data last year, the company is confident it can keep that momentum running well past the end of the decade.